Medis Consulting conducted a Systematic Literature Review (SLR) to document the evidence base linking hospital design elements on patient outcomes for a large global engineering firm.

Medis Consulting conducted an online survey in the US, Europe, and LATAM to quantify the value of various clinical profiles for an novel therapy in development for an ultra-orphan CNS indication.

A biotechnology company had brought their lead compound successfully through Phase 2 trials for a very rare endocrine disorder.  We helped them understand how their target clinicians would react to the existing data, and how best to generate compelling endpoints and measurements going forward.

A large global pharmaceutical company had identified auto-immune disorders as key targets for their R&D organization.  We conducted a Multi-Variable Analysis of a range of auto-immune diseases to evaluate opportunities while remaining product agnostic.

A large pharmaceutical company in partnership with a leading biologics company were preparing for the launch of a blockbuster monoclonal antibody in immunology.  They had full development programs for two indications in place, but felt the compound could address a variety of additional indications.  We conducted a Multi-Variable Analysis to recommend disease areas that provided opportunity and fit with this biologic.

A mid-sized biotechnology company had a portfolio of products all focused on orphan diseases.  They wanted to provide access to all patients around the globe, and asked us to evaluate the market access processes not only in leading industrialized markets, but across all countries where there might be significant patient need.